128 results about "Post immunization" patented technology

The invention discloses an influenza C virus HEF protein polyclonal antibody preparation method, which comprises: carrying out signal peptide prediction, antigen epitope screening and hydrophobicity analysis through bioinformatics, constructing a recombinant prokaryotic expression vector pET32a-HEF by using a seamless cloning technology, and efficiently expressing the HEF protein in Escherichia coli to obtain the influenza C virus HEF protein polyclonal antibody. The inclusion body protein yield is improved by optimizing conditions; and purifying by nickel column affinity chromatography to obtain high-purity recombinant protein, emulsifying the high-purity recombinant protein and a Freund's adjuvant, immunizing a Japanese white rabbit, immunizing for three times, and collecting high-titer serum. The method breaks through detection limitation caused by antigen tag concealment in a eukaryotic expression system, the obtained polyclonal antibody is high in specificity, the eukaryotic expression HEF protein can be accurately recognized, and a key tool is provided for ICV virus-like particle identification, vaccine research and development and diagnosis technologies. Compared with a traditional method, the scheme is simple and convenient to operate, low in cost and high in antibody titer, and has remarkable application value.

The invention discloses a porcine reproductive and respiratory syndrome virus RNA vaccine and application thereof, and relates to the technical field of veterinary biological products. According to the present invention, the coding sequence of the porcine reproductive and respiratory syndrome virus GP5 protein is optimized, and the GP5 protein is connected with the M protein through the connecting peptide, such that the saRNA prepared by using the nucleic acid molecule can produce the efficient expression on the GP5 protein and the M protein after the cell transfection. After the optimized porcine reproductive and respiratory syndrome GP5 protein and M protein fusion protein is immunized, the level of neutralizing antibodies generated by animals can be improved, and the effect of preventing the porcine reproductive and respiratory syndrome virus is achieved. Therefore, the nucleic acid molecule provided by the invention can be used for developing or preparing nucleic acid vaccines. Compared with a traditional vaccine, the vaccine provided by the invention has good immunogenicity and safety, and has a good application prospect.

The invention discloses a novel group B epidemic cerebrospinal meningitis outer membrane protein bifunctional vector, relates to the technical field of biopharmaceutical processes, and discloses a group B epidemic cerebrospinal meningitis outer membrane protein bifunctional vector and application thereof in epidemic cerebrospinal meningitis combined vaccinis.The bifunctional vector is human H factor binding protein fHbp and comprises two recombinant proteins BA and BB, the amino acid sequences of the amino acid sequences are respectively SEQ ID No. 62 and SEQ ID No. 63; the BA protein and the group A capsular polysaccharide are coupled to form a group A conjugate vaccine, the BB protein and the group C capsular polysaccharide are coupled to form a group C conjugate vaccine, the group A conjugate vaccine and the group C conjugate vaccine are mixed to form a group ABC triple vaccine, and each dose of the vaccine contains 40 micrograms of group A polysaccharide and 40 micrograms of group C polysaccharide, 160 micrograms of BA / BB protein and 1.0 mg of aluminum adjuvant; bA and BB proteins are expressed through escherichia coli and are subjected to high-pressure homogeneous crushing and anion exchange chromatography purification, and the purity is greater than or equal to 95%; the triple vaccine provided by the invention can simultaneously induce immune responses to group A, group B and group C meningococcal, the serum sterilization titer after first immunization is greater than or equal to 1: 32, and the titer after three immunization is maintained for more than 56 days.

This application belongs to the field of biology and discloses a strain of Candida tropicalis, which is classified and named candida tropicalis The deposit number is GDMCC NO: 65030; the deposit date is August 20, 2024, and it is deposited at the Guangdong Provincial Center for Microbiological Culture Collection, with the deposit address being: 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou. When fermented with this tropical yeast, Astragalus polysaccharide can enhance the immune-enhancing effect of Astragalus polysaccharide, stimulate animals to produce higher antibody titers after immunization, and reduce adverse immune reactions. The present invention also provides an Astragalus polysaccharide fermentation product, a preparation method, and applications.

The invention provides a novel ecological feed capable of preventing multiple grass-bream diseases, the novel ecological feed comprises a feed matrix and an ecological feed leavening agent, and the ecological feed leavening agent comprises probiotics with surface expression antigens, the antigen is any one or more of a grass carp reovirus antigen, a flavobacterium johnsonii antigen, an aeromonas veronii antigen and a clonorchis sinensis antigen. The novel ecological feed with a disease-resistant function in a parabramis pekinensis breeding mode is prepared for the first time, the resistance of the parabramis pekinensis to various pathogens can be enhanced, and the survival rate of the parabramis pekinensis in the disease attack peak period can be increased by 50% or above after immunization. An oral immunization mode is adopted and can be completed in the feeding process, and the immunization and breeding cost is greatly saved.

The invention discloses a conservative B cell epitope peptide of goose parvovirus VP3 protein, a nucleic acid molecule, a recombinant vector and application thereof. Conservative B cell epitope EW12 is inserted into F18 Escherichia coli Fod fimbriae, inert carrier bacteria S9H are introduced, recombinant bacteria capable of functionally exhibiting and expressing the EW12 conservative B cell epitope on the surface of the bacteria are obtained, the recombinant bacteria can specifically generate specific binding reaction with gosling plague egg yolk antibody and gosling plague vaccine immune serum, and the gosling plague egg yolk antibody and the gosling plague vaccine immune serum can be specifically combined with the gosling plague egg yolk antibody and the gosling plague vaccine immune serum. The method has the advantages that macroscopic agglutination particles are generated, cross agglutination reaction with other pathogen positive serum and healthy goose serum is avoided, the method is good in sensitivity, and the specific antibody can be detected in the 5th day after immunization at the earliest. A plate agglutination test directly mediated by the goose parvovirus VP3 protein conservative B cell epitope peptide EW12 has the advantages of specificity, sensitivity, convenience in operation and suitability for on-site large-scale rapid detection, and is expected to provide a new technical means for diagnosis, prevention and control and purification of GPV infection.

The invention is applicable to the field of genetic engineering, and provides a mycobacterium tuberculosis Mce1A-LS protein nanoparticle, a preparation method and application thereof, the mycobacterium tuberculosis Mce1A-LS protein nanoparticle is formed by sequence fusion of mycobacterium tuberculosis Mce1A protein and LS protein, and the amino acid sequence of the mycobacterium tuberculosis Mce1A-LS protein nanoparticle is shown as SEQ ID NO: 2 in a sequence table. The Mce1A-LS protein nanoparticle provided by the invention is high in immunogenicity, the protein Mce1A with high immunogenicity can induce to generate a synergistic immune effect and is high in safety, and the expressed fusion protein is non-toxic and harmless, so that the biosafety is high, in addition, the immune effect of the Mce1A-LS protein nanoparticle is good, and after the Mce1A-LS protein nanoparticle is used for immunizing a mouse, the immunogenicity of the Mce1A-LS protein nanoparticle is greatly improved. Strong body fluid and / or cellular immune response can be generated, which indicates that after immunization, a specific immune effect can be generated in a mouse body.

The invention mainly relates to a bovine rotavirus inactivated vaccine and a preparation method thereof, and according to the preparation method of the bovine rotavirus inactivated vaccine, ultrasonic emulsification conditions are as follows: the ultrasonic frequency is 24-28 kHz, the power density is controlled within the range of 0.6-0.8 W / cm, the single pulse time is 8-12 seconds, the ultrasonic time is 60-120 seconds, ultrasonic emulsification is carried out in a refrigerant bath at the temperature of 2-5 DEG C, the temperature fluctuation is + / -0.5 DEG C, and the ultrasonic time is 60-120 seconds. The virus content in the inactivated vaccine is greater than or equal to 5 * 10 < 5.0 > TCID50 / ml, and the neutralizing antibody titer within 21-49 days after secondary immunization is greater than or equal to 900. The prepared bovine rotavirus inactivated vaccine is subjected to ultrasonic emulsification, a generated neutralizing antibody can completely neutralize an RVA / Bovine-tc / CHN / SHH2023001 / 2023 / G10P [11] virus strain, the titer is high (the titer can reach 1700 or above at most), the duration time is long, the G10P [11] type bovine rotavirus is the most common virus infected in a dairy cow group, and the G10P [11] type bovine rotavirus can be used for preparing the vaccine. Therefore, the vaccine can be used as an alternative vaccine for preventing calves from being infected with bovine rotavirus.

The present application relates to the technical field of veterinary biological products, in particular to application of oridonin in preparation of poultry vaccine adjuvant. The poultry vaccine adjuvant is composed of oridonin, solvent and buffer. Experiments prove that after mixing the poultry vaccine adjuvant with poultry inactivated vaccine (such as Newcastle disease vaccine) for immunization, the humoral immune level of poultry can be significantly improved (HI titer of 21d after the second immunization is increased by more than 1.5 log2), and the secretion level of specific IgY (systemic immunity) and IgA (mucosal immunity) in serum can be extremely significantly up-regulated, and the high level of antibody is maintained for more than 4 weeks longer than that of the conventional vaccine group. Compared with commercial adjuvant ISA 201, the present application has better immune enhancement activity, high safety, no adverse reaction at injection site, and wide clinical application prospect.

The application discloses a preparation method of a novel inhalable anthrax component vaccine based on a mutant strain of anthrax bacillus, and relates to the technical field of immunology medicine. The application provides a mutant strain of anthrax bacillus, and a mutant strain A16R-5.1 with six extracellular protease activity related genes deleted. The vaccine is extracted from the culture supernatant of anthrax prepared by using the mutant strain A16R-5.1, and can induce strong humoral, cellular and mucosal immune responses after immunization, can resist the invasion of anthrax spores, and can neutralize anthrax toxin in an in-vitro experiment.

The invention relates to the field of veterinary biological products, in particular to a porcine epidemic diarrhea virus attenuated strain and a vaccine and application thereof. The porcine epidemic diarrhea virus attenuated strain provided by the invention is obtained through in-vitro separation culture and continuous five rounds of plaque purification and screening technology, and has stable culture characteristics. Meanwhile, the virulence of the strain on newborn piglets and weaned piglets is remarkably reduced, and the virulence does not have the phenomenon of reversion after continuous passage for five times in a pig body. The strain has good immunogenicity, and mucosal immunity and systemic immune response of an organism can be activated at the same time by adopting an oral immunization mode. A neutralizing antibody of 1: 8-1: 16 can be detected in oral fluid and serum after the piglets are immunized for 14 days, and a large amount of sIgA is generated in milk after the pregnant sows are immunized, so that the piglets obtain effective passive immune protection.

The present invention relates to the field of immunoassay technology and provides a bifenthrin hapten, antigen, antibody, preparation method, and application thereof. The bifenthrin hapten provided by the present invention completely retains the molecular structure of bifenthrin. After coupling with a carrier protein, the immunogenicity of the resulting antigen is significantly improved, and the prepared antibody has stronger specificity and higher sensitivity. The results of the examples show that the bifenthrin hapten provided by the present invention is coupled with a carrier protein, and the resulting antigen, after injection into mice for immunization, produces an antibody titer of 1×10 4 , half inhibitory concentration (IC 50 ) is about 20ppb, and the minimum detection limit of colloidal gold for bifenthrin in dry tobacco leaf samples is about 1.25μg / g.

The invention relates to a recombinant rabies virus. The recombinant rabies virus is obtained by inserting an antigen gene of feline calicivirus and an antigen gene of feline herpes virus into a genome of a rabies virus attenuated strain. The triple inactivated vaccine for preventing and treating the feline calicivirus disease, the feline herpes virus disease and / or the rabies is prepared based on the recombinant rabies virus, and after the triple inactivated vaccine is used for immunizing cats, neutralizing antibodies aiming at the feline calicivirus disease, the feline herpes virus disease and the rabies virus can be effectively induced and generated; the simultaneous immunization on the three viruses is realized.

The invention provides a triple tetravalent inactivated vaccine for preventing and treating duck viral diseases and application of the triple tetravalent inactivated vaccine, and belongs to the technical field of biological vaccines. A water phase of the vaccine is prepared by matching a type 1 duck hepatitis virus antigen solution, a type 3 duck hepatitis virus antigen solution and a duck reovirus antigen solution, and then adding a duck parvovirus VP2 protein solution to obtain a mixed antigen solution with the final concentration of 40 mu g / ml, the virus content in the type 1 duck hepatitis virus antigen solution and the virus content in the type 3 duck hepatitis virus antigen solution are 106.5 ELD50 / 0.2 ml, and the virus content in the duck reovirus antigen solution is 106.5 ELD50 / 0.2 ml. And the virus content of the duck reovirus antigen is 105.5 TCID50 / ml. The four antigen components in the vaccine are free of mutual interference, good in safety and exact in immune effect, the vaccine can achieve the purpose of preventing multiple diseases by one injection, the stress response of the duck immune vaccine is reduced, meanwhile, the four virus diseases are susceptible to small-day-age ducks, and invasion of the four viruses can be prevented at the same time after immunization. The vaccine preparation method is simple and convenient, and the production cost is greatly reduced.

The application discloses a recombinant pseudorabies virus strain expressing classical swine fever virus E2 protein and application, and relates to the technical field of biology.The recombinant E2 protein provided by the application successfully realizes high-level expression of the E2 protein by removing the transmembrane region of the E2 protein and using the 18aa signal peptide of the E2 protein itself and a pig albumin signal peptide.The recombinant PRV expressing the classical swine fever virus (CSFV) E2 protein can induce E2 antibodies and cellular immunity after immunization of mice.The recombinant pseudorabies virus strain provided by the application can be used as a bivalent vaccine for preventing CSFV and PRV infection.

The invention belongs to the field of biological products and the field of nucleic acid vaccines, and particularly relates to a virus (oropravirus)-like particle, preparation and application of the virus (oropravirus)-like particle as a vaccine. The virus-like particles are Oropers virus-like particles, and the virus-like particles contain proteins encoded by M genome segments of OROV strains or proteins encoded by gene segments of the M genome segments and N proteins of the OROV strains; wherein the corresponding sequence can also be a consistency sequence with the similarity of 75% with the corresponding sequence. Meanwhile, the particle VLP is used as a serum binding antibody of an antigen and an evaluation method of a T cell reaction, and the method can be used for detecting a serum lifting method after vaccine immunization. The invention further provides five nucleic acid vaccines for coding different functional domains of the OROV and combinations thereof, the immunogenicity and T cell reaction induced by the nucleic acid vaccines under different design strategies are displayed, strong body fluid and cell reaction is still kept 154 days after immunization, and it is proved that the nucleic acid vaccines can induce lasting and efficient immune reaction, and the immunogenicity and the T cell reaction are not influenced. The method can be used as a technical reserve and has huge clinical significance and application scenarios.

This application discloses a recombinant hemagglutinin protein, its uses, expression methods, and subunit vaccines, belonging to the field of biomedical technology. The technical solution is as follows: a recombinant hemagglutinin protein, obtained by removing the transmembrane and intracellular regions of the HA protein sequence of the H7N9-235 strain and fusing a T4-foldon sequence at the C-terminus; or by retaining the full-length sequence of the HA protein of the H7N9-235 strain. The amino acid sequence of the recombinant hemagglutinin protein is shown in SEQ ID NO.1 or SEQ ID NO.2. The application also discloses a recombinant hemagglutinin protein with good immunogenicity and medical prospects based on the H7N9 strain. Furthermore, when a subunit vaccine is prepared using the recombinant hemagglutinin protein with the transmembrane and intracellular regions removed, the immunogenicity after secondary immunization is significantly enhanced.

The present invention discloses a rabies inactivated vaccine diluent and its preparation method and application, belonging to the technical field of vaccine diluents. The invention provides an inactivated vaccine diluent to solve the technical problems of low antibody titer, long production time and short antibody maintenance time after animal inactivated vaccine immunization. The invention provides a rabies inactivated vaccine diluent, which is composed of the following components: phosphate buffer, MONTANIDE TM GEL 02 PR adjuvant, canine interferon, and ricin B chain protein. This diluent can significantly increase the rabies neutralizing antibody titer after rabies inactivated vaccine administration.

The invention discloses a method for preparing a sheep-derived positive serum reference of yersinia enterocolitica, obtained positive serum and application of the positive serum, and belongs to the field of veterinary medicine products. The invention aims to solve the technical problem of how to obtain the yersinia enterocolitica sheep-derived positive serum reference which is stable in titer and character and can be used for specific detection of brucella diagnostic products. Therefore, the invention provides a method for preparing the yersinia enterocolitica sheep-derived positive serum reference, which comprises the following steps: immunizing a tested sheep by using an immunizing antigen, and collecting serum of the immunized tested sheep to obtain the yersinia enterocolitica sheep-derived positive serum reference. The immune antigen is an inactivated yersinia enterocolitica obtained by inactivating the yersinia enterocolitica. The positive serum reference can be effectively applied to quality control evaluation work of brucellosis related diagnosis products, and plays a positive role in prevention and control of brucellosis.

The application discloses an egg yolk antibody against Nocardiosis and a preparation method and application thereof, and relates to the technical field of biological medicines. A light chain sequence of the egg yolk antibody comprises a sequence shown in SEQ ID NO. 1, and a heavy chain sequence comprises a sequence shown in SEQ ID NO. 2. The application expands culture of pathogenic bacteria Nocardia, prepares an inactivated bacterin vaccine, and immunizes hens, so that the hens produce egg yolk antibodies against Nocardia through an immune response. After immunization, the application collects eggs, extracts the egg yolk antibodies against Nocardiosis from egg yolk by using a water dilution method. It is verified that the egg yolk antibodies have a strong binding capacity with Nocardia, can effectively inhibit Nocardia, and the titer can reach 1:64000 at the highest.

The invention discloses a foot-and-mouth disease inactivated vaccine immunologic adjuvant composition. The foot-and-mouth disease inactivated vaccine immunologic adjuvant composition comprises a TLR4 agonist, a TLR9 agonist, an anionic surfactant and a cationic high-molecular polymer. The weight ratio of the TLR4 agonist to the TLR9 agonist to the cationic high-molecular polymer to the anionic surfactant is (50 to 150): (50 to 150): (800 to 1100): (1 to 5). The foot-and-mouth disease inactivated vaccine immunologic adjuvant composition provided by the invention not only can provide protective activity for foot-and-mouth disease antigens, but also has the advantages of fast antibody production and high antibody production level after animal immunization, so that animals can obtain good immune protection.

The invention provides an FcRn-targeted Brucella multi-epitope nano vaccine, which can realize long-term protection, shows continuous immune memory, has high-frequency hair-growing central B cells (GCB), follicular helper T cells (TFH) and central memory T cells (TCM), and ensures long-term immune surveillance; even six months after immunization, the serum IgG titer is still obviously higher than that of a control group; efficient antigen delivery can be achieved, specifically, a chitosan-based nano-particle system is adopted, and antigen protection and intestinal epithelium uptake are enhanced through FcRn targeted ligand modification; the delivery efficiency can be improved by 10 times, and the gastrointestinal mucosal barrier is overcome; in addition, rapid immune starting can be achieved, multi-dimensional immune response is induced within 14 days after final immunization, and rapid protection is provided for resisting brucella infection.

The application belongs to the technical field of molecular biology, and particularly relates to an anti-CD28 nanobody and a preparation method and application thereof. The anti-CD28 nanobody provided by the application is prepared in the following manner: constructing a CD28 antigen to immunize a llama, constructing a phage library to the PBMC of the immunized llama, screening the phage library, selecting correct sequences to construct and express and purify, and finally obtaining the anti-CD28 nanobody through cell function detection screening. The nanobody provided by the application has specific recognition and binding capacity for CD28, has the advantages of high specificity, high sensitivity and the like, effectively reduces the development and production cost of the CD28 antibody, and shortens the expression time of the antibody.

To provide vaccines and methods.SOLUTION: Described herein are methods for identifying optimized antigenic pathogen polypeptides capable of inducing a broadly neutralizing immune response and associated T-cell responses to a pathogen, and nucleic acid sequences encoding such polypeptides. Also described are methods for determining whether a broadly neutralizing immune response is induced in a subject following immunization with an optimized antigenic pathogen polypeptide or a nucleic acid encoding the optimized pathogen polypeptide. Further described are nucleic acid molecules, polypeptides, vectors, cells, fusion proteins, pharmaceutical compositions, and their use as vaccines against pathogens, especially against emerging or re-emerging pathogens (particularly RNA viruses).SELECTED DRAWING: None

The purpose of the present invention is to provide, as a platform technique that may serve as preparation for pandemics, a rapid antibody production technique in which a non-human animal having a human antibody gene is used. More specifically, the purpose of the present invention is to provide an immunization method with which it is possible to induce, in a short period of time, a high antigen-binding ability of an antibody or a high antibody titer of an antiserum, and a method for producing a human antibody / antiserum with which it is possible to rapidly produce a wide range of neutralizing antibodies.　(1) An immunization method for rapidly inducing a human monoclonal antibody having a high ability to bind to a desired antigen or a human polyclonal antibody having a high antibody titer, the method comprising a step for immunizing a non-human animal a plurality of times with a desired antigen or a nucleic acid encoding the antigen within 30 days from the first immunization, the non-human animal having a human antibody gene or locus, and the non-human animal being such that an endogenous gene or locus of the non-human animal corresponding to the human antibody gene or locus is disrupted or deleted, or mutated so as to result in a loss of expression or low expression. (2) A method for producing a human antibody against a desired antigen using a non-human animal, the method comprising: an immunization step for immunizing the non-human animal with the antigen or a nucleic acid encoding the antigen; a human immunoglobulin-positive B cell isolation step for isolating B cells that are human immunoglobulin-positive from a tissue of the immunized non-human animal; an antibody base sequence acquisition step for acquiring the base sequences of antibody light-chain mRNA-derived cDNA and antibody heavy-chain mRNA-derived cDNA prepared from the isolated B cells; and an antibody production step for producing an antibody on the basis of the acquired antibody base sequence, the non-h

The application discloses a novel group B meningococcal outer membrane protein bifunctional carrier, relates to the technical field of biopharmaceutical processes, and discloses a group B meningococcal outer membrane protein bifunctional carrier and application of the bifunctional carrier in a meningitis combined vaccine. The bifunctional carrier is human H factor binding protein fHbp, and comprises two kinds of recombinant proteins BA and BB, and the amino acid sequences of the two kinds of recombinin proteins are SEQ ID No. 62 and SEQ ID No. 63 respectively. The BA protein is coupled with group A capsule polysaccharide to form a group A combined vaccine, the BB protein is coupled with group C capsule polysaccharide to form a group C combined vaccine, and the two are mixed to form a group ABC triple vaccine. Each dose of the triple vaccine contains 40 μg of group A / C polysaccharide, 160 μg of BA / BB protein in total and 1.0 mg of aluminum adjuvant. The BA and BB proteins are expressed by E. coli, are broken by high-pressure homogenization, and are purified by anion exchange chromatography, and the purity is greater than or equal to 95%. The triple vaccine can simultaneously induce immune responses to groups A, B and C of meningitis, the serum bactericidal titer is greater than or equal to 1:32 after primary immunization, and the titer is maintained for more than 56 days after three immunizations.

The present invention discloses a charge mutant antigen of the receptor binding domain (RBD) of the novel coronavirus, and the mutant is obtained by adding consecutive negatively charged amino acids to the end of the RBD of the novel coronavirus receptor binding domain. Compared with the wild-type RBD antigen, the RBD antigen mutant can significantly increase the neutralizing antibody level of the host against the novel coronavirus after immunization with AL(OH)3 adjuvant. The present invention also provides the application of the RBD antigen mutant in the preparation of drugs or vaccines for the treatment and prevention of the novel coronavirus.

The invention relates to the technical field of tuberculosis vaccines, in particular to a tuberculosis VLP nanoparticle vaccine and preparation and application thereof. According to the tuberculosis VLP nanoparticle vaccine, through up-regulation of Th1 type, Th2 type and TH17 type cellular immune response and down-regulation of Treg cellular immune response, the H37Rv growth inhibition ability of splenic lymphocytes and lung cells in vitro is enhanced, and the cellular immune response induced by EPPE + mi3 / AS01E and the H37Rv growth inhibition ability of the cells in vitro are higher than those of BCG and a corresponding subunit vaccine EPPE / AS01E; in addition, the EPPE + mi3 / AS01E can be used as a BCG booster vaccine, and the cell immune response after BCG immunization and the H37Rv growth inhibition capacity of cells in vitro are improved.

The invention discloses a breeding informatization management system based on intelligent agriculture big data, and relates to the technical field of big data management, and the system comprises a breeding file establishment module which is used for taking the specific immune response intensity and stability of a target pathogen as core breeding indexes, screening excellent parents to construct a basic breeding group, and establishing a breeding file; establishing a breeding file containing pedigree, genotype and immune related molecular markers; the immune archive binding module is used for creating a structured immune archive for the individual based on the archive and binding a unique identifier; the immune program formulating module is used for formulating differentiated immune programs according to genetic background layering; the immune program optimization module is used for scanning an identifier at an immune spot to automatically match an optimization scheme; and the multi-index combined seed selection module is used for quantifying the post-immune titer index into a new breeding character and feeding the new breeding character back to the breeding system, so that closed-loop optimization is realized. According to the method, the breeding efficiency, the immune precision and the group disease resistance can be remarkably improved.

The invention discloses a method for improving the expression quantity and immunogenicity of a novel plant-derived coronavirus RBD-sc-dimer, and claims to protect a recombinant plasmid, and the recombinant plasmid comprises an optimized target protein sequence. The optimized target protein sequence sequentially comprises a gene sequence of a signal peptide as shown in a sequence 2, a gene sequence of a target protein dimer and a nucleotide sequence as shown in a sequence 8 from the 5'end to the 3 'end; the optimized target protein sequence is positioned behind the 35S promoter in the plasmid. According to the plant source protein prepared through the recombinant plasmid, RBD-sc-dimer is fused with 10 serine-proline dipeptides, and secretory expression is achieved through an SSExt signal peptide. Experimental results show that by means of the design, the expression quantity of RBD-sc-dimer can be increased by 2.4 times, and the total IgG level after three times of immunization of 10 g of recombinant protein is increased by about 100 times.